Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$74 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.5
Industry P/E
--
EV/EBITDA
-0.6
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$--
EPS
$-1.9
Face value
--
Shares outstanding
60,573,400
CFO
$-110.45 Mln
EBITDA
$-60.60 Mln
Net Profit
$-289.71 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Acumen Pharmaceuticals Inc (ABOS)
| -30.2 | 12.1 | -5.5 | -48.5 | -28.6 | -- | -- |
|
BSE Sensex
| 5.3 | 0.4 | 9.2 | 6.6 | 17.1 | 18.9 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Acumen Pharmaceuticals Inc (ABOS)
| -54.9 | -28.9 | -20.1 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Acumen Pharmaceuticals Inc (ABOS)
|
1.2 | 73.9 | 0.0 | -116.3 | -- | -62.4 | -- | 0.5 |
| 49.9 | 8,093.9 | 1,208.8 | 131.7 | 13.4 | 6.3 | 61.9 | 3.9 | |
| 128.2 | 8,285.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 147.5 | 7,242.1 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 53.0 | 9,911.0 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 40.4 | 11,277.9 | 2,298.9 | 643.6 | 35.4 | 29.2 | 18.9 | 5.3 | |
| 52.8 | 6,644.1 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14.4 | 13.6 | |
| 309.4 | 8,699.8 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.1 | 14.7 | |
| 25.9 | 9,881.3 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 126.6 | 12,599.3 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.4 | 4.9 |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a... recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts. Address: 1210-1220 Washington St., Newton, MA, United States, 02465 Read more
CEO & Director
Mr. Daniel J. O'Connell M.B.A.
CEO & Director
Mr. Daniel J. O'Connell M.B.A.
Headquarters
Newton, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Acumen Pharmaceuticals Inc (ABOS) stood at $ 224 Mln as on 31-Mar-25
The share price of Acumen Pharmaceuticals Inc (ABOS) is $1.20 (NASDAQ) as of 20-Jun-2025 16:00 EDT. Acumen Pharmaceuticals Inc (ABOS) has given a return of -28.62% in the last 3 years.
Acumen Pharmaceuticals Inc (ABOS) has a market capitalisation of $ 74 Mln as on 18-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Acumen Pharmaceuticals Inc (ABOS) is 0.48 times as on 18-Jun-2025, a 83% discount to its peers’ median range of 2.78 times.
Since, TTM earnings of Acumen Pharmaceuticals Inc (ABOS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Acumen Pharmaceuticals Inc (ABOS) and enter the required number of quantities and click on buy to purchase the shares of Acumen Pharmaceuticals Inc (ABOS).
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts. Address: 1210-1220 Washington St., Newton, MA, United States, 02465
The CEO & director of Mr. Daniel J. O'Connell M.B.A.. is Acumen Pharmaceuticals Inc (ABOS), and CFO & Sr. VP is Mr. Daniel J. O'Connell M.B.A..
There is no promoter pledging in Acumen Pharmaceuticals Inc (ABOS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,260
|
|
|
1,128
|
|
|
991
|
|
|
988
|
|
|
870
|
|
|
829
|
|
|
809
|
|
|
742
|
|
|
664
|
| Acumen Pharmaceuticals Inc (ABOS) | Ratios |
|---|---|
|
Return on equity(%)
|
-62.38
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Acumen Pharmaceuticals Inc (ABOS) was $0 Mln.
$-0.02
(
